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The serotonin transporter (5-HTT) is a key mechanism regulating magnitude and duration of 
serotonergic transmission in the central nervous system, and is the site of action of selective 
serotonin reuptake inhibitors (SSRIs) used for treating psychiatric conditions. Variation in 
treatment response to SSRIs has been correlated with a common bi-allelic length polymorphism 
in the 5-HTT-promoter region (5-HTTLPR), known to modulate transcriptional efficiency of the 
5-HTT gene in vitro. The alleles, designated long (l) or short (s), result in one of three possible 
genotypes:  l/l, l/s, or s/s.  The (s) allele has been hypothesized to have a dominant functional 
effect, and has been associated with decreased transporter transcription efficiency and poorer 
therapeutic response to antidepressants. Acute transporter blockade with SSRIs rapidly increases 
central nervous system serotonin levels, leading to hypothalamic receptor stimulation and the 
release of several hormones, including prolactin.  The specific aim of this study is to characterize 
the prolactin response to acute 5-HTT-reuptake blockade according to 5-HTTLPR genotype, to 
further elucidate the effect of this polymorphism on serotonin transporter function in vivo.  This 
study has been designed to test the hypothesis that, when compared to subjects with the l/l 
genotype, subjects with either the s/l or s/s genotype will experience a blunted prolactin response 
following acute administration of the highly selective reuptake inhibitor Citalopram.  To 
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accomplish this goal, a cohort of 206 community volunteers were intravenously administered a 
weight-adjusted dose of Citalopram.  Each subject was genotyped for the 5-HTTLPR, and blood 
samples were obtained for prolactin and Citalopram levels immediately before and at regular 
intervals for 2.5 hours after the Citalopram injection.   Results:   Citalopram-induced prolactin 
response, reported as prolactin area under the curve (PRL AUC), was significantly associated 
with 5-HTTLPR (F = 3.08, p = 0.048).  Among individuals with the s/s genotype, PRL AUC 
response (M±SD: 84.2 ± 51.8 ng/ml * 150min) was significantly lower (p = 0.014) than the l/l 
group (246.0 ± 40.2 ng/ml * 150 min).  The difference in PRL AUC between subjects with the l/l 
genotype and the l/s group (172.5 ± 41.3 ng/ml * 150 min) was not significant (p = 0.21); the 
difference in PRL AUC between subjects with the l/s genotype and the s/s group also was not 
significant (p = 0.23).  When results were analyzed as the maximum change in prolactin, the 
Citalopram-induced PRL MAX was similarly associated with 5-HTTLPR (p = 0.034).  
Conclusions:  Subjects with the 5-HTTLPR s/s genotype exhibit significantly lower prolactin 
response in response to the SSRI Citalopram than subjects carrying two copies of the l allele.  
The s allele does not have a dominant effect on the prolactin response to Citalopram in a non-
patient population. 
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1. INTRODUCTION 
 
1.1. SEROTONIN IN THE CENTRAL NERVOUS SYSTEM 
Central nervous system serotonin (5-HT) is synthesized in neurons whose cell bodies lie in the 
brainstem raphe nuclei.  Raphe 5-HT neurons form complex pathways in the human brain, 
consisting of at least five main 5-HT pathways into the forebrain as well as myriad branches to 
other neuronal pathways, which form global and local networks.  Raphe nuclei fibers project to 
virtually every part of the brain, including limbic structures, hypothalamus, hippocampus, 
substantia nigra, and all cortical areas.  Raphe neurons send collateral inputs to the limbic 
system, believed to modulate mood and behavior, and the hypothalamus, which regulates 
hormone secretion.  Therefore, serotonin dysregulation, which has been implicated in a variety of 
mood and behavioral disorders, may also be reflected in plasma hormone concentrations.  The 
serotonin transporter (5-HTT) is a key mechanism in the regulation of serotonergic activity, and 
is the site of action of serotonin reuptake inhibitors (SSRIs).  SSRIs have proven to be clinically 
effective in treating many, but not all individuals suffering from mood and behavioral disorders.  
Consequently, much attention has been focused on discovering sources of variation in 5-HTT 
function to elucidate inter-individual variation in treatment response to SSRIs and future 
treatment strategies.  
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1.2. PREVIOUS RESEARCH 
 
1.2.1. Differential biological responses to SSRIs suggest 5-HTT functional variation 
 
Biological indices of post-synaptic serotonergic activity in individuals undergoing treatment with 
SSRIs were originally utilized to help clarify the differences in treatment responses between 
individuals.  For instance, variations in biological indices of central 5-HT function following 
administration of SSRI’s, such as levels of cerebrospinal fluid 5-hydroxyindoleacetic acid (CSF 
5-HIAA) (Asberg et al., 1981; Insel et al., 1985; Thoren et al., 1980), platelet [3H] imipramine 
binding (Castrogiovanni et al., 1995; Tollefson et al., 1996), and platelet or plasma serotonin 
levels (Blardi et al., 2002; Figueras et al., 1999), have been found to correlate with individual 
differences in therapeutic response to SSRIs, suggesting possible inter-individual differences in 
transporter function and/or availability.  A recent study using SPECT imaging to quantify 5-HTT 
availability reports better treatment response to SSRI’s in subjects with greater pre-treatment 
transporter availability (Kugaya et al., 2004).   
Researchers investigated variation in the serotonin transporter genetic sequence, in hopes of 
discovering a functional polymorphism to explain a functional effect on the protein itself, but 
none have been identified to date.  However, recent investigations focusing on a functional 
polymorphism in the 5-HTT gene linked promoter region (5-HTTLPR) have provided insight 
into variability in post-synaptic serotonergic activity. 
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1.2.2. Isolating 5-HTT functional variation  
Functional variation in the promoter region of the 5-HTT contains a common 44 base pair 
insertion/deletion, giving rise to a bi-allelic polymorphism designated long (l) and short (s).  In 
human platelet studies, this sequence variation has been shown to have functional consequences 
that modulate the gene’s transcriptional efficiency and affect the rate of 5-HT transport from the 
extracellular space into the cell (reuptake).  The (l) and (s) variants of the 5-HTTLPR have 
different transcriptional efficiencies when fused to a reporter gene and transfected into human 
placental choriocarcinoma (JAR) cells.  The deletion, or (s) allele reduces transcriptional 
efficiency roughly twofold (Lesch et al., 1996; Heils et al., 1996).  In cultured lymphoblasts, the 
(s) allele is associated with lower 5-HTT-gene promoter and 5-HTT gene expression, and 
decreased serotonin uptake (Lesch et al., 1996). 
In vivo studies have shown that, compared to the (l) variant of the 5-HTTLPR, the (s) 
allele is associated with poorer therapeutic response to antidepressants (Arias et al., 2003; 
Zanardi et al., 2001; Pollock et al., 2000; Zanardi et al., 2000; Smeraldi et al., 1998), although 
the results of one study, utilizing a Korean population (Kim et al., 2000), associated the (s) allele 
with a significantly better response. 
Other in vivo studies addressing functional properties of the 5-HTTLPR are informative, 
although not always consistent.  For instance, the (s) allele may be associated with lower 
midbrain 5-HTT mRNA expression and transporter availability (Little et al., 1998; Heinz et al., 
2000), reduced uptake of serotonin into platelets (Greenberg et al., 1999; Nobile et al., 1999), 
and lower whole blood serotonin content (Hanna et al., 1998), but these findings are not reported 
in all studies.  For instance, Willeit et al. (2001) found no significant difference in transporter 
availability between 5-HTTLPR genotype groups, assessing SPECT imaging of [123]I-beta-CIT 
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binding in vivo.  Stoltenberg et al. (2002) reported no association between 5-HTTLPR and whole 
blood serotonin content in their study population.  With respect to characterizing the effects of 
the 5-HTTLPR allelic variation on serotonin transporter function, these studies are not ideal due 
to a number of factors:  1) small sample size – none of which had greater than 70 subjects, with 
the exception of the Stoltenberg study which included 150 subjects; 2) current subject pathology 
such as obsessive-compulsive disorder (Hanna et al., 1998), major depression (Nobile et al., 
1999), and alcoholism (Heinz et al., 2000) – psychiatric illness and long-term alcohol 
dependence have been shown to alter transporter availability, although it is not clear to what 
degree; and 3) use of homogenized postmortem brain tissue (Little et al., 1998), analysis of 
which is likely to be confounded by post-mortem delay, storage time, differences in brain region, 
and ante mortem treatment with antidepressants.  
In two large studies involving healthy volunteers, cerebrospinal fluid (CSF) concentrations 
of the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA), (an indirect estimate of 5-HT 
turnover in the brain) were compared with individual 5-HTTLPR genotype.  Jönsson et al., 
(1998) reported no association of CSF 5-HIAA and 5-HTTLPR genotype in 66 healthy subjects.  
However, in a more recent study, CSF 5-HIAA was found to be 50% higher in persons with 
either one or two l alleles than those of persons with the s/s genotype (Williams et al., 2001).  
Although CSF 5-HIAA has been reported as an index of central serotonergic activity, the 
conflicting results from these studies suggested the need to measure a more direct biological 
correlate of transporter function.  
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1.2.3. Neuroendocrine Response to Transporter Blockade 
Another method to measure variation in 5-HT function in vivo is to assess neuroendocrine 
response to drugs that alter serotonergic neurotransmission.  In what are referred to as 
neuroendocrine challenge tests, plasma levels of pituitary hormones such as prolactin are 
measured to quantify the change in hypothalamic 5-HT receptor stimulation following 
administration of serotonergic agents that have known effects on enzymatic degradation, pre or 
post synaptic receptors, or reuptake (Raap and Van de Kar, 1999 Review). 
By utilizing a serotonergic agent with an action specific to a particular mechanism, such 
as that of an SSRI on the serotonin transporter, functional effects of allelic variation can be 
compared as variation in rapid increase of synaptic 5-HT availability indexed by prolactin 
response.  5-HTTLPR allelic variation associated with variation in prolactin response to 
administration of SSRIs provides insight into the effect of the polymorphism on transporter 
availability and variation in treatment response.   
The effect of 5-HTTLPR allelic variants in in vivo CNS serotonergic activity has been 
assessed using prolactin response to acute administration of various antidepressants.  Two recent 
studies suggest that neuroendocrine response to pharmacological alteration of the serotonin 
transporter mechanism varies by 5-HTTLPR genotype.  Women homozygous for the short allele 
exhibited smaller elevations in plasma prolactin concentration following acute administration of 
the tri-cyclic antidepressant clomipramine, relative to women carrying two copies of the long 
allele (Whale et al., 2000).  In the second study, males having at least one short variant of the 
promoter polymorphism also showed a blunted prolactin response to the 5-HT releasing agent, 
fenfluramine, compared to men homozygous for the long allele (Riest et al., 2001). 
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Although the blunted prolactin responses reported in these two studies among participants 
with either the s/s or s/l genotype are consistent with one another, the serotonergic agents used 
limit the interpretation of the effect of genotype on transporter function.  For instance, Whale et 
al. (2000) utilized clomipramine as the neuroendocrine challenge agent, which has mixed 
serotonergic and noradrenergic effects, making it difficult to attribute the rise in plasma prolactin 
exclusively to alteration in serotonin transporter function.  In the Reist study, fenfluramine was 
the challenge agent used, which acts as a releasing agent as well as a reuptake inhibitor. 
Although fenfluramine produces a measurable prolactin response, the effect of the compound on 
transporter directionality complicates interpretation of the effect the genotype may have on 
transporter availability and normal transporter function.  Additionally, the Reist study (2001) had 
the added complication of the study subjects having been pooled from individuals with alcohol 
dependence, which may itself compromise transporter availability. 
 
1.2.4. Present Study Rationale and Purpose 
To more accurately characterize the effect of the 5-HTTLPR on transporter-mediated variation in 
serotonergic activity, the design of this study rectifies some limitations of prior work, such as 
sample size, psychopathology, and pharmacological selectivity.  The large sample size (n = 206) 
affords statistical power missing in previous studies.  In addition, this community sample is 
screened to identify current major psychiatric disorders, alcohol dependence, and recent 
antidepressant exposure, all of which may be correlated with altered transporter function and 
availability.  Lastly, the pharmacological agent used, Citalopram, is the most highly selective 
SSRI currently available, does not affect 5-HT release, and does not directly act at any 5-HT  
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receptors (Milne et al. 1991).  Citalopram’s profile isolates the pharmacological manipulation to 
the transporter reuptake mechanism, which is essential in order to associate changes in plasma 
prolactin with allelic variation in 5-HTTLPR.   
The purpose of this study is to test possible associations between 5-HTTLPR allelic 
variation and variability in central nervous system serotonergic responsivity, as measured by 
neuropharmacological challenge, in a large community sample of healthy adults. In this 
experiment, I will test the hypothesis that, when compared to subjects with the l/l genotype, those 
subjects with one or two copies of the s allele (the s/l and s/s genotypes) will experience blunted 
prolactin responses following acute administration of the highly selective SSRI Citalopram.  
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2. RESEARCH DESIGN  
 
2.1. SUBJECT CRITERIA 
 
Subjects were recruited from the local population in the Pittsburgh area, and met the following 
criteria:  good general health without reported clinical history of atherosclerotic disease; angina 
or peripheral arterial disease; severe and chronic diseases affecting general health (e.g., cancer 
[diagnosed or treated within the past year], chronic kidney or liver disease, multiple sclerosis).  
Subjects also were free of current major depression, and not taking any of the following 
disallowed medications:  antidepressants; narcotics daily; anxiolytics daily; antimanics; 
antipsychotics; anticovulsants; antiparkinson; glucocorticoids; or weight loss medications (i.e., 
orlistat, sibutramine hydrochloride, or phenteramine hydrochloride).   
 
2.2. CITALOPRAM CHALLENGE PROTOCOL 
 
Following informed consent, participants reported to the General Clinical Research Center at 
UPMC-Montefiore Hospital and were administered a single, weight-adjusted dose of Citalopram, 
with subsequent sampling of blood for prolactin concentrations under the following conditions:  
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The session began between 13:30 and 15:00 hours, during the time of the day when plasma 
prolactin levels are relatively stable.  Studies (Katznelson et al. 1998; Sassin, et al. 1972) have 
shown that prolactin levels are highest during sleep and just after waking, and lowest in the early 
to late afternoon hours.  Citalopram dose is calculated by multiplying each subject’s lean body 
mass, in kilograms, by 0.33 mg (subjects stand on an automated body composition analyzer that 
calculates fat free mass based on measured electrical impedance).  To minimize the effects of 
caloric intake on circulating drug levels, Citalopram was administered following a 2-hour fast 
(water only).  Because alcohol may affect serotonergic function (LeMarquand et al., 1994) 
subjects were instructed to refrain from drinking alcohol for 24 hours prior to their session.  
Because menstrual phase can affect prolactin response (O’Keefe et al. 1991; Wada et al. 1991), 
pre-menopausal women completed the challenge protocol during the early follicular phase (e.g., 
days 3-9) of the menstrual cycle.  In addition, screening for cocaine and heroin was completed 
prior to the administration of Citalopram, with a positive result for either substance immediately 
ending the subject’s participation in the study.    Upon verification of negative drug screen 
results, an IV catheter was inserted into each forearm, one for drug administration and the other 
for blood sampling.  After a 30-minute rest period, subjects received Citalopram intravenously 
over 30 minutes, which was controlled by standard infusion pump.  Ten blood samples (between 
4.5 – 6.5 ml each) were obtained for prolactin beginning -5 minutes and -1 minute before 
medication administration, and +30, +45, +60, +75, +90, +105, +120, and +150 minutes after 
initiation of the infusion.   
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3. RESEARCH METHODS 
 
3.1. MOLECULAR GENETIC STUDIES 
 
Genomic DNA was isolated from EDTA anticoagulated whole blood by standard procedures.  
The 5-HTTLPR site was assayed by DNA amplification of the sequence by the polymerase chain 
reaction (PCR) method using 0.3 µM of sequence flanking primers 5’-GAG GGA CTG AGC 
TGG ACA ACC AC-3’ and 5’-GGC GTT GCC GCT CTG AAT GC-3’.  The PCR reaction was 
carried out in a total volume of 30µl, with 1.5 µl DNA, 200 µM each dATP, dCTP, dTTP, and 
100 µM dGTP, 1.83 mM MgCl2, and 1.2 µl Taq polymerase.  The PCR product was analyzed 
following electrophoresis on an ethidium bromide stained 2% agarose gel. 
     
3.2. BIOLOGICAL ASSAYS 
 
3.2.1. Serum Prolactin 
Serum prolactin was measured using an enzyme-linked immunoabsorbent assay kit obtained 
from Diagnostic Systems Labs (DSL, Webster, TX USA).  Standards, controls, and unknown 
serum samples are incubated in 96-well plates that have been coated with anti-prolactin antibody.  
After incubation and washing, the wells are treated with another anti-prolactin detection antibody 
labeled with the enzyme horseradish peroxidase.  After a second incubation and washing step, 
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the wells are incubated with the substrate tetramethylbenzidene.  An acidic stopping solution is 
then added and the degree of enzymatic turnover of the substrate is determined by dual 
wavelength absorbance measurement at 450 and 620 nm.  The absorbance measured at 450 nm is 
directly proportional to the concentration of prolactin present.  The assay is linear from 1.5 to 90 
ng/ml, with a between-assay coefficient of variation from 2.5-8.2%.    
 
 
3.2.2. Plasma Citalopram Levels   
Citalopram is extracted from plasma using liquid-liquid extraction along with high-performance 
liquid chromatography and ultraviolet detection, at wavelength 210 nm (Pollock et al. 1997).  
One ml of plasma is alkayzed using carbonate buffer, and then extracted using ethyl acetate in 
heptane (20:80, v/v) and back-extracted into 0.025M potassium phosphate buffer.  The HPLC 
column for separation is a C18 5µm Nucelosil column, 120 x 4.6 mm i.d. from Knauer, 
Germany.  The flow rate is 1.0 ml/minute. The assay is linear from 5 to 500 ng/ml for all 
compounds. Citalopram elutes at a retention time of  6.78 minutes for Citalopram and 10.00 
minutes for the internal standard, Paroxetine.  Inter-assay variation of spiked plasma ranges from 
1.76-7.32 % C.V. for Citalopram.  
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3.3. STATISTICAL METHODS 
 
Data was analyzed using SPSS (Statistical Package for the Social Sciences) Software® (version 
12.1, SPSS, Inc. Chicago, IL USA), with the exception of stated manual computations.  SPSS is 
a comprehensive software package designed for statistical data analysis.   For the present 
analyses, the following SPSS modules were utilized:  1) descriptive statistics, to determine 
means, standard deviations, standard errors, variance, minimum and maximum values, and 
confirm normal distribution for all variables of interest; 2) t-tests to compare means of 
independent samples when appropriate; 3) one-way analysis of variance, to test for significant 
differences in group means; 4) Pearson correlations; and 5) linear regression analysis.  All tests 
were two two-tailed, with the probability value p ≤ 0.05 constituting statistical significance. 
  
3.3.1. Population Stratification Test 
A Chi-square test statistic was used to analyze potential differences in genotype frequencies 
between African American and Caucasian subjects.   
 
3.3.2. Hardy Weinberg Equilibrium Test  
A Chi-square test statistic comparing the cohort’s observed vs. expected genotype distribution 
under the Hardy-Weinberg Equilibrium Law was manually calculated. 
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3.3.3. Calculation of the Dependent Measure 
The dependent measure of interest, change in plasma prolactin concentration (ng/ml) following 
Citalopram administration, was calculated for each subject using two methods: 1) change in 
prolactin area under the curve (PRL AUC); and 2) maximum change in prolactin from baseline 
(PRL MAX).  Results are reported separately for each method. 
PRL AUC provides a value that includes the total prolactin response over all time points 
(Pruessner et al., 2003) for each subject, minus their baseline prolactin concentration.  It should 
be noted that two baseline prolactin measurements were taken, one at t = -1 and one at t = -5.  
The correlation between the t-1 and t-5 measurements was highly significant (r = 0.98), so the 
average of the two time points was used as the baseline value.  PRL AUC was calculated using 
the trapezoid rule, which sums the area between each successive blood sample [(PRL baseline + 
PRL t1)/2 *time)+((PRL t2 + PRL t3)/2 *time)…((PRL t8 +PRL t9) – (PRL baseline * (total 
time)).  Thus, PRL_AUC = ((PRL baseline + prl30)/2 * 15) + ((PRL30 + PRL45) * 7.5) + 
((PRL45 + PRL60) * 7.5) + ((PRL60 + PRL75) * 7.5) + ((PRL75 + PRL90) * 7.5) +  ((PRL90 + 
PRL105) * 7.5) + ((PRL105 + PRL120) * 7.5) + ((PRL120 +  PRL150) * 15) – (Baseline * 150). 
PRL MAX is arrived at using each subject’s maximum prolactin value over the 150-minute 
protocol.  The baseline average is then subtracted out of the peak value, using linear regression 
analysis, which removed any correlation of PRL MAX with baseline prolactin values.  The linear 
regression analysis estimate the coefficient value (in this case baseline prolactin) and subtracts 
that value from the dependent measure (PRL MAX), creating an new value that is ‘residual’, or 
the value that remains after the baseline average is removed.  The residualized value becomes the 
dependent measure, PRL MAX, which has a zero correlation with baseline prolactin.   
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3.3.4. Preliminary Data Analysis – Assessing Potential Covariates 
Factors that have been known to correlate with prolactin response to serotonergic stimulation are 
age (McBride et al., 1990), plasma drug levels (Judson et al., 2003; Lotrich et al., 2004), and 
body mass index (Muldoon et al., 1996, 2004).  Pearson correlations or t-tests were performed on 
each of these variables with PRL AUC, in order to assess their appropriate inclusion into the 
model as covariates. 
Additionally, baseline prolactin levels may exhibit seasonal variability (Brewerton, 
1989).  Season was compared with baseline PRL using two separate measurements.  First, season 
was dichotomized by:  1= March 21st through September 20th, and 2= September 21st through 
March 20th, and seasonal means were compared for significant differences.  Season was also 
compared using minutes of daylight. Because women have higher baseline PRL values, groups 1 
and 2 were analyzed by gender composition, and found to have an equal distribution of men and 
women within each season.  
Other factors that may affect neuroendocrine function are reproductive status in women 
(van Amelsvoort et al., 2001) and sleep deprivation (Seifritz, et al., 1997).  Individuals with 
alcohol dependence have been shown to exhibit reduced midbrain transporter availability (Heinz 
et al., 1998, 2000) and blunted neuroendocrine responses to serotonergic stimulation 
(Anathenelli et al., 2000).  Thus, t-tests were performed, comparing PRL AUC and PRL MAX 
with women’s reproductive status (dichotomized as premenstrual and postmenstrual), sleep 
deprivation (defined as working past 12:00 a.m. within 2 days of the session), and alcohol 
dependence (determined according to criteria established in the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition). 
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3.3.5. Primary Data Analysis 
Univariate ANOVA was performed with 5-HTTLPR genotype and gender as independent 
measures and  PRL AUC as the dependent measure.  The same analysis was undertaken using 
PRL MAX as the dependent measure.  Results are reported for both methods of calculating the 
dependent measure.   
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4. RESULTS 
 
4.1. POPULATION STRATIFICATION 
 
There was a highly significant difference in allele frequency between the African American (n = 
73 - 77% l allele/23% s allele) and Caucasians (n = 277 - 56% l allele/44% s allele) groups (Chi-
square = 15.3, p< 0.001), precluding analysis of the two ethnic groups together (Gelertner et al., 
1997).  Consequently, in this sample, only 3 of the 73 African American subjects had the s/s 
genotype, which was not enough to test the hypothesis under separate analysis, and so this 
population was not further considered.  
4.2.  STUDY POPULATION 
 
The original sample included 346 subjects.  From those 346 initial participants, the following 
subjects were removed from the dataset due to the following:  the 73 African American subjects 
were removed due to population stratification (see section 4.1), 26 subjects voluntarily withdrew; 
11 subjects experienced emesis (an independent source of prolactin increase) and their prolactin 
data were unusable; 18 subjects had incomplete prolactin or Citalopram data; 1 subject had 
baseline prolactin of greater than 50 ng/ml (normal physiological range is between 4 and 35 
ng/ml); 3 subjects had PRL AUC values that were greater than 4 standard deviations from the 
mean and were removed as outliers;  2 subjects had Citalopram drug levels that were greater than 
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4 standard deviations from the mean and were removed as outliers; 6 women were taking oral 
contraceptives (not considered exclusion medications at the onset of the study, but found to have 
significantly higher mean prolactin levels (refer to Section 4.4), so women taking oral 
contraceptives had their data removed from the dataset.  The final study population sample is 
comprised of 206 unrelated healthy Caucasian volunteers, 127 men and 79 women.  The age 
range of the study population is 30-55 years (45.1 ± 0.45), with no significant difference in mean 
age between men and women  (t .05, 204 = -0.21, p = 0.84).   
 
4.3. 5-HTTLPR GENOTYPE FREQUENCIES 
 
The study sample, n=206, had the following genotype distribution: 74 l/l; 85 l/s; 47 s/s; resulting 
in a Chi-square = 5.4, 0.05 < p< 00.10, which conforms to the Hardy Weinberg Equilibrium 
theory.  Genotype frequency was not significantly different between gender groups (Chi-square 
= 2.27, p > 0.32). 
 
4.4. INCLUSION/EXCLUSION OF COVARIATES 
 
Although age has been found to correlate significantly with prolactin response in other challenge 
studies, there was no significant correlation of age with PRL AUC  (r = -0.01, p = 0.90) or PRL 
MAX (r = -0.020, p = 0.77) and therefore age was excluded as a covariate. This cohort 
encompassed a relatively narrow age range, from 30-55, likely accounting for the lack of 
correlation in this sample (See Table 1). 
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No significant association of seasonal variation with Baseline PRL was found using 
either by dichotomizing season (t.05, 204  = 1.17, p = 0.24) or when taken as total minutes of 
daylight (r = -0.12, p = 0.94).   There was no difference in participant’s gender distribution 
within seasons (X2 .05,1 = 0.61, p = 0.43). 
BMI was found to significantly correlate with PRL AUC and PRL MAX responses (r = -
0.19, p = 0.006; r = -0.21, p = 0.002) and, following square root transformation to normalize the 
distribution of BMI, was included as a covariate (see Table 1).    
Individual differences in plasma Citalopram levels may partially account for variation in 
prolactin response between subjects.  In order to minimize drug concentration differences 
between subjects, variation in body size was accounted for by calculating the Citalopram dose 
according to fat free mass (0.33 mg/kg), but there remained significant variation in post-infusion 
plasma Citalopram levels between subjects, particularly at +30 minutes (M±SD 54.2 ± 19.0 
ng/ml).    Therefore, both plasma Citalopram at +30 minutes (CTL 30) and plasma Citalopram 
area under the curve (CTL AUC) values were tested for significant correlation with PRL AUC 
and PRL MAX.  Although CTL AUC and CTL30 were both significantly associated with PRL 
AUC and PRL MAX, CTL AUC showed a slightly higher correlation and was the plasma 
citalopram measurement included as a covariate in the analysis of variance (see Table 1).  CTL 
AUC was not significantly different according to genotype group (see Table 2). 
PRL AUC was not found to be significantly correlated with menopausal status, alcohol 
dependence, or sleep deprivation (see Table 1).  However, the use of oral contraceptives did 
significantly correlate with mean PRL AUC (t.05,84 = -2.7, p = 0.01), and data from the 6 subjects 
who were currently taking oral contraceptives were excluded from the analysis (see Table 1). 
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Plasma Citalopram level (CTL AUC) and body mass index (BMI) were identified as 
covariates and were included in the model.  Additionally, because baseline PRL was still 
significantly associated with PRL AUC (r = -0.245, p = 0.001), baseline PRL was included as a 
covariate in the PRL AUC analysis.  There was no significant difference in age, gender, or BMI 
between genotype groups (see Table 2). 
 
TABLE 1:  Relations of Potential Covariates with PRL Measures  
 
 PRL AUC PRL MAX 
Age r = -0.017             p = 0.81 r = -0.02            p = 0.77 
BMI r = -0.19               p = 0.006* r = -0.21            p = 0.002* 
Pre/post menopause (n = 53/26) t.05,77 = -1.8           p = 0.07 t.05,77 = -1.3        p = 0.20 
Oral Contraceptive Use (n = 6) t.05,84 = -2.7           p = 0.01* t.05,84 = 1.5         p = 0.15 
Alcohol Dependence (n = 12) t.05,204 = -0.55       p = 0.59 t.05,204 = -0.42     p = 0.68 
Sleep Deprivation (n = 11) t.05,204 = 0.58        p = 0.56 t.05,204 = 0.57      p = 0.57 
Citalopram AUC r = -0.14              p = 0.04* r = -0.17            p = 0.02* 
Citalopram +30 min r = -0.12              p = 0.08 r = -0.16            p = 0.025* 
 
 
TABLE 2:  Sample Characteristics by Genotype 
  
   L/L L/S S/S Sig. 
Age  44.9 ± 0.75 
 
45.2 ± 0.69 
 
45.4 ± 0.94 
 
0.92 
BMI 27.1 ± 0.59 
 
27.2 ± 0.55 
 
27.3 ± 0.74 
 
0.97 
 
Baseline PRL (ng/ml) 9.4 ± 0.54 
 
110.03 ± 0.51 
 
9.7 ± 0.68 
 
0.08 
CTL AUC (ng/ml *150) 2633.5 ± 65.5 2595.0 ± 61.1 2581.3 ± 82.2 0.86  
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4.5. PRIMARY RESULTS 
 
The 5-HTTLPR is significantly associated with area under the curve prolactin response to acute 
administration of Citalopram (F=3.1, p=0.048) (See Table 3).  Compared to the l/l carriers (246.0 
± 40.2 ng/ml * 150 min), subjects with the s/s (84.2 ± 51.8 ng/ml * 150 min) genotype exhibited 
lesser increases in plasma prolactin.  Pair wise comparison by genotype revealed a significantly 
lower prolactin response in the s/s group relative to the l/l group (p = 0.014).  No significant 
difference was noted when comparing either the s/s group to the l/s group (p = 0.17), or the l/s 
group to the l/l group (p = 0.23) (See Table 4).  
When the data are analyzed as maximum prolactin rather than area under the curve then 
results are essentially the same.  The 5-HTTLPR is significantly associated with maximum 
prolactin response to acute administration of Citalopram (F= 3.5, p= 0.034) (See Table 3).  
Compared to the l/l carriers (3.69 ± 0.054 ng/ml), subjects with the s/s (3.46 ± 0.07 ng/ml) 
genotype exhibited lesser increases in plasma prolactin.  Pair wise comparison by genotype 
revealed a significantly lower prolactin response in the s/s group relative to the l/l group (p = 
0.01), with the s/s and l/s groups approaching but not reaching statistical significance (p = 
0.056).  No significant difference was noted when comparing the l/s group to the l/l group (p = 
0.43) (See Table 4).  
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TABLE 3:  Univariate Analysis of Variance 
 
               PRL AUC  PRL MAX  
   
 Source Df F P value 
 
Df F P value 
CTL AUC 1, 197 4.7 0.031  1, 198 4.8 0.03 
BMI 1, 197 9.7 0.002  1, 198 9.8 0.002 
BASELINE PRL 1, 197 15.5 0.001     
GENDER 1, 197 0.12 0.73  1, 198 0.12 0.73 
5-HTTLPR 2, 197 3.1 0.048  2, 198 3.5 0.034 
GENDER*GENO 2, 197 1.06 0.35  2, 198 0.05 0.95 
 
 
TABLE 4:  Pairwise Comparisons by Genotype 
       
   PRL AUC  PRL MAX  
 
 Mean Difference 
 
Sig. 
 
Mean Difference 
 
Sig. 
 
l/l x s/s 147.8  0.02 (*) 0.23  0.01 (*) 
 
l/l x l/s 74.6 0.17 0.06 0.43 
 
l/s x s/s -73.3  0.23 -0.17 0.056 
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5. DISCUSSION 
 
The major finding in this study is that Citalopram-induced prolactin response is associated with 
the 5-HTTLPR genotype (See Figures 1 & 2).  Individuals with the s/s genotype have 
significantly lower prolactin responses than individuals with the l/l genotype.  The s allele does 
not have a dominant effect on the prolactin response to Citalopram, as there is no significant 
difference in prolactin response between individuals with the l/s genotype and l/l genotype or the 
l/s and s/s genotypes.      
The results of this study replicate previous associations of variation in prolactin response 
to SSRIs with the 5-HTTLPR. Importantly, this study was carried out using Citalopram, a highly 
selective serotonin reuptake inhibitor that does not act directly at 5-HT receptors, which is 
essential in order to associate individual differences in plasma prolactin response with proposed 
genetically-driven 5-HTT functional variation.  This is the first study to characterize the 
association of the 5-HTTLPR on prolactin response to Citalopram in a relatively large (n=206) 
non-patient sample, including women and men.  
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5.1. PROLACTIN RESPONSE  
 
The mean prolactin response reported in this study replicates the results of previous 
neuroendocrine studies utilizing Citalopram.  Seifrietz et al., (1996) reported  prolactin 
maximum change (M±SD: 17.80 ± 4.65 ng/ml) to 20 mg. IV Citalopram.  The results reported 
herein (M±SD: 13.34 ± 5.83 ng/ml), are quite comparable, although by using a weight-adjusted 
dose (M±SD: 18.98 ± 3.78 mg) our prolactin response was slightly smaller (Lotrich et al. 2004).  
Attenburrow et al. (2001) used 10 mg IV Citalopram and placebo to compare within-subject 
differences in change in prolactin area under the curve.  They found a significant difference (p = 
0.01) in prolactin responses between the placebo (-2.2 ± 21.3 ng/ml *150 min) and 10mg. 
Citalopram (67.1 ± 26.7 ng/ml *150 min) treatments.  The PRL AUC response in the current 
study (180.8 ± 25.7 ng/ml *150 min) was more pronounced than in the Attenborrow study (67.1 
± 26.7 ng/ml *150 min), presumably due to the larger Citalopram dose used in the present study 
(0.33 mg/kg vs. 10 mg). 
For practical reasons, it is not standard to use a placebo control in studies of this size.  
However, in a smaller (n=75) study, Lotrich et al. (2004) compared prolactin response to placebo 
with a range of Citalopram doses (10mg, 0.33 mg/kg, 20 mg, and 40 mg).  Lotrich’s results 
indicated a linear dose-dependent increases in prolactin and, at the 0.33 mg/kg dose the increase 
was ~3.5 ng/ml (max change), which compares to the findings in this study (3.6 ± 0.26 ng/ml).  
Lotrich found no within-subject correlation of prolactin response between citalopram and 
placebo, indicating the variability in response is not related to individual physiological responses 
to the procedure or to temporal changes in prolactin. 
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FIGURE 1:  Prolactin area under the curve group means during the Citalopram Challenge Test 
by 5-HTTLPR genotype. 
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FIGURE 2:  Prolactin maximum (max) change group means during the Citalopram Challenge 
Test by 5-HTTLPR genotype.  
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5.2. PROPOSED MOLECULAR MECHANISMS:  TRANSPORTER VARIATION 
 
The results of this study confirm the findings of Whale et al. (2000) and Reist et al. (2001) that 
prolactin response to antidepressants varies by 5-HTTLPR genotype.  In contrast to the challenge 
agents used in the Whale & Reist studies, citalopram results in pharmacological manipulation to 
the transporter reuptake mechanism only, providing evidence that differences in prolactin 
response are related to transporter function.  A growing body of evidence indicates that the s/s 
genotype is associated with reduced transporter availability, suggesting two possible molecular 
explanations for reduced prolactin response in the s/s subjects following acute 5-HT reuptake 
inhibition with citalopram:  1) less hypothalamic serotonergic neurotransmission under steady 
state conditions in individuals with the s/s genotype, and 2) relative hyper-sensitivity of the raphe 
nuclei somatodendritic autoreceptors in individuals with the s/s genotype. 
Evidence exists for relatively less serotonergic activity in individuals with the s/s 
genotype.  Williams et al. (2001) reported 50% more 5-HIAA in cerebrospinal fluid of subjects 
with either one or two copies of the l alleles, relative to subjects with the s/s genotype.  Similarly, 
Hanna et al., (1998) found lower whole blood serotonin in subjects with the s/s genotype 
compared to the l/s or l/l individuals.  While lower CSF 5-HIAA and blood serotonin levels are 
not conclusive evidence of reduced hypothalamic serotonergic activity in s/s individuals, they 
may reveal a tendency towards less CNS 5-HT neurotransmission, which may be reflected in 
prolactin response to neuroendocrine challenge and treatment response to SSRIs.    
Alternately, inter-individual variability in the change in plasma prolactin following acute 
5-HTT blockade is not a direct reflection of hypothalamic post-synaptic 5-HT levels, but may 
reflect variability in the dynamics of pre-synaptic molecular mechanisms that has developed 
under chronically inefficient transporter transcription.  The somatodendritic autoreceptor (5-
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HT1a) feedback mechanism may be one regulatory mechanism that would undergo a 
developmental change.  For instance, if reduced transcriptional efficiency results in less 5-HTT 
(Little et al., 1998; Heinz et al., 2000) to remove 5-HT from raphe nuclei extracellular fluid, 5-
HT1a receptors may be intrinsically up regulated.  Thus, under conditions where postsynaptic 
(hypothalamic) 5-HT are equivalent between s/s and l/l individuals prior to the challenge, 
relatively greater 5-HT1a activation may inhibit firing rates in subjects with the s/s genotype 
immediately following transporter blockade.  Relatively greater inhibition of firing rates via 5-
HT1a activation would then lead to reduced hypothalamic stimulation and relatively less 
prolactin release in s/s individuals.  A similar, but far more complex scenario could also be 
constructed involving differences in postsynaptic mechanisms that may develop according to 5-
HTTLPR genotype. 
It is likely that functional imaging techniques will be employed in future genetic studies 
to further quantify the associations between 5-HTTLPR genotype, transporter function, and 
neuroendocrine response to SSRIs.  Citalopram is indicated in imaging studies, as these data 
show clearly that it’s selective action on the serotonin transporter elicits a centrally-mediated 
response that varies depending on the 5-HTTLPR s and l alleles.  
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5.3. OTHER DETERMINANTS OF PROLACTIN RESPONSE  
 
Data was collected on factors that have been associated with between-subjects differences in 
prolactin response:  season, women’s productive status, age, gender, sleep deprivation, and 
alcohol dependence.  Although no correlations were found between any of these variables and 
variation in prolactin response in this population, it was important to rule these variables out as 
confounders.  Likewise, study subjects were screened to rule out recent anti-depressant exposure 
and current major depressive disorder diagnosis, as either of these conditions could affect 
serotonergic function and prolactin results.   
There are other possible genetic determinants of prolactin response to reuptake inhibitors 
that should, in future studies, be evaluated separately and in interaction with the 5-HTTLPR.  A 
case in point is the CYP219 gene – a genetic polymorphism in this enzyme is known to effect 
citalopram metabolism.  Dopamine receptor polymorphisms are also candidate genes for this 
area of research as rat studies have demonstrated dopamine’s role in tonic inhibition of prolactin 
release.  Estrogen and cortisol receptor polymorphisms are also of interest, as they may exert 
significant influences on both gene transcription and hypothalamic regulation of hormone 
secretion. 
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5.4. CONCLUDING STATEMENT 
 
The purpose of this investigation was to help clarify effects of genetic variation occurring in the 
promoter region of the serotonin transporter gene that may, by exerting effects on transporter 
transcription efficiency, reflect individual differences in serotonergic neurotransmission after 
treatment with SSRIs.  Gene transcription is a highly complex molecular process - transcription 
factors and variation within enhancer, silencer, and promoter sequences downstream of the 5-
HTT gene may also exert influences on 5-HTT transcription. 
Acknowledging these additional sources of variability in 5-HTT transcription and other 
genes involved with 5-HT regulation, hypothalamic stimuli magnitude, and Citalopram 
metabolism does not diminish the validity of the association of the 5-HTTLPR with prolactin 
response reported in this community sample.  The results of this study provide additional 
evidence of a significant, genetically driven source of inter-individual variation in 5-HT 
regulation, further supporting the study of pharmacological-genetics in the treatment of 
psychiatric disease.      
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